The DCPS Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of A-549 human lung adenocarcinoma epithelial cells with targeted disruption of the DCPS gene. This model eliminates the scavenger decapping enzyme, enabling functional studies of mRNA turnover and quality control. As a heterogeneous pool of knockout cells, it provides a robust, cost-effective tool for functional genomics and drug target validation without requiring single-cell isolation.
The A-549 parental cell line originated from a lung adenocarcinoma of a 58-year-old Caucasian male. These epithelial cells serve as a model for human alveolar type II cells and are widely used in lung cancer and respiratory research. A-549 cells retain key oncogenic signaling pathways and drug response profiles, making them a relevant platform for studying tumor biology and therapeutic vulnerabilities. Their well-characterized genome and robust growth support knockout-based experiments.
DCPS encodes a scavenger mRNA decapping enzyme that hydrolyzes the m7GpppN cap from short mRNA fragments produced by 3??-to-5?? exonucleolytic decay, completing mRNA turnover and preventing accumulation of capped intermediates. DCPS functions within the mRNA surveillance pathway and is linked to nonsense-mediated decay (NMD). It acts downstream of the decapping complex, interacting with DCP1A, DCP2, EDC4, and the exonuclease XRN1, and also associates with exosome components (EXOSC2, EXOSC3) and cap-binding proteins (NCBP1, NCBP2). Additional factors like LSM1 are involved. DCPS indirectly modulates expression of targets such as SMN2, relevant to spinal muscular atrophy, thereby acting as a key regulator of global transcript stability.
In A-549 lung adenocarcinoma cells, DCPS knockout allows investigation of how altered mRNA decay impacts cancer cell proliferation, migration, and drug sensitivity. Since DCPS inhibition is explored therapeutically in oncology and spinal muscular atrophy, this model is valuable for studying cellular adaptations to chronic DCPS loss and for drug target validation. It provides a clinically relevant context for examining the intersection of mRNA metabolism and tumor biology.
This knockout product supports diverse applications including mRNA decay mechanistic studies, functional genomics, and drug discovery. Researchers can validate knockout via western blotting and RT-qPCR, perform transcriptome-wide RNA-seq, and conduct cap hydrolysis and co-immunoprecipitation assays with interacting partners like DCP1A and XRN1. Phenotypic analyses using viability and migration assays further extend its utility in cancer biology. For technical inquiries, please contact Ascent Research.
